CASE REPORT
Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children
 
More details
Hide details
1
Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
 
2
Department of Paediatric Infectious Diseases, Regional Hospital of Infectious Diseases, Warsaw, Poland
 
 
Submission date: 2024-03-28
 
 
Final revision date: 2024-05-13
 
 
Acceptance date: 2024-05-14
 
 
Publication date: 2024-09-20
 
 
Corresponding author
Maria Pokorska-Śpiewak
Prof. Maria Pokorska-Śpiewak, Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
 
 
Pediatr Pol 2024;99(3):266-269
 
KEYWORDS
TOPICS
ABSTRACT
Sofosbuvir/velpatasvir (SOF/VEL) is a safe and effective regimen used for the treatment of chronic hepatitis C. The standard treatment duration is 12 weeks. There are no data available to support the shortened treatment. We aimed to present a case of an 11-year-old boy treated with a generic SOF/VEL for 8 weeks. The patient was admitted to our department 12 weeks after the end of treatment to establish the efficacy of the therapy (sustained virological response, SVR12). Laboratory testing revealed aminotransferases and bilirubin levels within the normal ranges, there were no abnormalities in the abdomen ultrasound, and transient elastography did not reveal any liver fibrosis. Hepatitis C virus (HCV) RNA tested with reverse-transcription polymerase chain reaction method was undetectable. The patient achieved SVR12. We conclude that shortening treatment with SOF/VEL to 8 weeks may be effective for HCV elimination in children. The possibility of treatment shortening should be confirmed in further studies on larger groups of paediatric patients.
REFERENCES (19)
1.
Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol 2020; 5: 374-392.
 
2.
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4: 477-487.
 
3.
Modin L, Arshad A, Wilkes B, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2019; 70: 371-378.
 
4.
Pokorska-Śpiewak M, Dobrzeniecka A, Lipińska M, Tomasik A, Aniszewska M, Marczyńska M. Liver fibrosis evaluated with transient elastography in 35 children with chronic hepatitis c virus infection. Pediatr Infect Dis J 2021; 40: 103-108.
 
5.
Updated recommendations on treatment of adolescents and children with chronic HCV infection: policy brief. Geneva: World Health Organization 2022. Licence: CC BY-NC-SA 3.0 IGO.
 
6.
Indolfi G, Gonzalez-Peralta RP, Jonas MM, et al. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings. J Pediatr Gastroenterol Nutr 2024.
 
7.
Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, Lucenteforte E. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta-analysis. Liver Int 2024.
 
8.
Malik F, Bailey H, Chan P, et al. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. JHEP Rep 2021; 3: 100227.
 
9.
Pokorska-Śpiewak M, Talarek E, Aniszewska M, et al. Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C-Results of the PANDAA-PED study. Liver Int 2023; 43: 1871-1878.
 
10.
Sokal E, Schwarz KB, Rosenthal P, et al. Safety and efficacy of sofosbuvir/belpatasvir for the treatment of chronic hepatitis C infection in adolescents and children aged 3 to 17 years old through 24 weeks post-treatment. Hepatology 2020; 72: 570A.
 
11.
Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis c virus: part 1 of the DORA study. Hepatology 2020; 71: 456-462.
 
12.
Epclusa (sofosbuvir/velpatasvir) use for 8 weeks. Medical information. Gilead sciences. Available from: https://www.askgileadmedical.c... (accessed: 07.03.2024).
 
13.
Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis c virus infection: a randomized trial. Ann Intern Med 2015; 163: 818-826.
 
14.
Efficacy and safety of sofosbuvir containing regimens for the treatment of chronic HCV infection in participants with chronic genotype 1, 2, 3, or 6 HCV infection. ClinicalTrials.gov Identifier: NCT01826981 [study results].
 
15.
Maasoumy B, Ingiliz P, Spinner CD, et al. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: the HepNet acute HCV-V study. JHEP Rep 2023; 5: 100650.
 
16.
Boyle A, Marra F, Peters E, et al. Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. J Viral Hepat 2020; 27: 371-375.
 
17.
Matthews GV, Bhagani S, Van der Valk M, et al. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol 2021; 75: 829-839.
 
18.
Serranti D, Dodi I, Nicastro E, et al. Shortened 8-week course of sofosbuvir/ledipasvir therapy in adolescents with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2019; 69: 595-598.
 
19.
National Hepatitis Elimination Profile, Ukraine. Coalition for Global Hepatitis Elimination. Updated July 23, 2023. Available from: https://www.globalhep.org/site.... (accessed 10.05.2024).
 
Journals System - logo
Scroll to top